Cleaved-F2 (R327) Antibody

What is the Cleaved-F2 (R327) Antibody and what does it specifically recognize?

The Cleaved-F2 (R327) Antibody is a polyclonal antibody raised in rabbits against a synthesized peptide derived from the internal region of human Thrombin APII (also known as coagulation factor II). This antibody specifically recognizes the cleaved form of the protein at arginine 327 (R327) within the internal region (approximately amino acids 250-330) . Coagulation factor II undergoes proteolytic cleavage to form thrombin during the first step of the coagulation cascade, which ultimately results in the stemming of blood loss . The antibody detects endogenous levels of the cleaved protein with high specificity, making it valuable for studying thrombin activation and related pathways.

What applications is the Cleaved-F2 (R327) Antibody validated for?

The Cleaved-F2 (R327) Antibody has been validated for the following research applications:

The antibody has been tested and verified using HeLa and Jurkat cell lines, particularly cells treated with etoposide (25μM for 24 hours) . Western blot analysis consistently shows detection of a band at approximately 19-20 kDa, which represents the cleaved form of thrombin, although the calculated molecular weight of the full protein is approximately 70 kDa .

What is the molecular basis for the observed molecular weight (19-20 kDa) versus calculated weight (70 kDa)?

The discrepancy between the observed molecular weight of 19-20 kDa and calculated molecular weight of 70 kDa results from the proteolytic processing of prothrombin (F2) . Prothrombin is a precursor protein that undergoes sequential cleavage during activation. The 70 kDa represents the full-length prothrombin, while the 19-20 kDa band observed in Western blots represents one of the cleaved fragments containing the R327 epitope that the antibody specifically recognizes . This cleavage is physiologically significant as it represents the activation process of thrombin in the coagulation cascade. Understanding this difference is crucial for properly interpreting experimental results and avoiding misidentification of bands in Western blot analyses.

What are the optimal storage conditions for the Cleaved-F2 (R327) Antibody?

For optimal preservation of antibody activity, the following storage conditions are recommended:

• Store at -20°C or -80°C upon receipt

• Avoid repeated freeze-thaw cycles, as this can denature the antibody and reduce its binding efficacy

• The antibody is supplied in PBS buffer containing 50% glycerol, 0.5% BSA/protective protein, and 0.02% sodium azide at pH 7.4, which helps maintain stability during storage

• Prior to use, centrifuge the vial to ensure complete recovery of the contents, as recommended by the manufacturer

These storage conditions help maintain antibody integrity and performance in research applications over extended periods.

How does the Cleaved-F2 (R327) Antibody compare with other thrombin detection methods in detecting coagulation abnormalities?

The Cleaved-F2 (R327) Antibody offers specific advantages over other thrombin detection methods, particularly in investigating coagulation abnormalities. Unlike functional assays that measure thrombin activity, this antibody directly detects the cleaved protein, providing evidence of thrombin activation regardless of its enzymatic activity . This feature is particularly valuable when studying mutations in F2 that lead to various forms of thrombosis and dysprothrombinemia .

Comparative analysis with other methods reveals:

The choice between these methods should be based on the specific research question, with the Cleaved-F2 (R327) Antibody being particularly useful for studying the molecular mechanisms of thrombin processing rather than just its activity.

What is the significance of F2 cleavage at R327 in relation to vascular integrity and thrombotic disorders?

The cleavage of F2 at R327 represents a critical step in the activation of thrombin and subsequent coagulation cascade. Research indicates that this specific processing event has significant implications for vascular integrity and the development of thrombotic disorders . F2 plays a role beyond hemostasis, including maintaining vascular integrity during development and postnatal life .

The R327 cleavage site is particularly important because:

• It generates active thrombin fragments that regulate the coagulation cascade

• Improper cleavage due to mutations near this site can lead to dysprothrombinemia

• Altered cleavage patterns affect thrombin's interaction with its substrates and inhibitors

• The cleaved fragments have been shown to have distinct biological activities, including antimicrobial properties against E. coli and P. aeruginosa from C-terminal peptides

Monitoring this specific cleavage event using the Cleaved-F2 (R327) Antibody allows researchers to gain insights into these processes and potentially identify novel therapeutic targets for thrombotic disorders.

How can the Cleaved-F2 (R327) Antibody be utilized in studies investigating the antimicrobial properties of thrombin-derived peptides?

The unique ability of the Cleaved-F2 (R327) Antibody to recognize the specific cleaved form of thrombin makes it an invaluable tool for investigating the antimicrobial properties of thrombin-derived peptides . Research has shown that peptides derived from the C-terminus of F2 exhibit antimicrobial activity against E. coli and P. aeruginosa .

Methodological approaches for such studies include:

• Isolation and characterization of thrombin-derived antimicrobial peptides:

  • Using the antibody for immunoprecipitation of cleaved thrombin fragments

  • Confirming fragment identity via Western blot with the Cleaved-F2 (R327) Antibody

  • Testing isolated fragments for antimicrobial activity

• Mechanistic studies of antimicrobial action:

  • Tracking the localization of cleaved fragments in bacterial cultures using immunofluorescence

  • Correlating fragment presence with bacterial membrane disruption

  • Monitoring bacterial killing in relation to fragment concentration

• Structure-function relationship analysis:

  • Comparing the activity of natural cleaved fragments with synthetic peptides

  • Using the antibody to confirm structural similarities between synthetic and natural forms

  • Identifying the minimal peptide sequence required for antimicrobial activity

These approaches leverage the specificity of the Cleaved-F2 (R327) Antibody to advance understanding of the dual role of thrombin in hemostasis and host defense.

What is the optimal protocol for using Cleaved-F2 (R327) Antibody in Western blotting?

The following protocol is optimized for detecting cleaved thrombin with the Cleaved-F2 (R327) Antibody in Western blotting applications:

Sample Preparation:

• Extract proteins from cells using a standard lysis buffer (e.g., RIPA buffer with protease inhibitors)

• For induced samples, consider treatments that activate the coagulation cascade (e.g., etoposide 25µM for 24 hours as validated in Jurkat cells)

• Determine protein concentration using a standard assay (BCA or Bradford)

• Prepare samples in Laemmli buffer with a reducing agent and heat at 95°C for 5 minutes

SDS-PAGE and Transfer:

• Load 20-50 µg of protein per lane

• Separate proteins using 10-15% SDS-PAGE (use 12% for optimal resolution of the 19-20 kDa cleaved product)

• Transfer to PVDF or nitrocellulose membrane (PVDF recommended for higher sensitivity)

Immunoblotting:

• Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Dilute Cleaved-F2 (R327) Antibody in blocking buffer at 1:500-1:2000 (start with 1:1000)

• Incubate membrane with diluted antibody overnight at 4°C with gentle rocking

• Wash membrane 3-5 times with TBST, 5 minutes each

• Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Wash 3-5 times with TBST, 5 minutes each

• Develop using ECL substrate and detect signal

Expected Results:

• A specific band at approximately 19-20 kDa representing the cleaved form of thrombin

• Positive control: HeLa or Jurkat cell lysates (particularly Jurkat cells treated with etoposide)

• Depending on cell type and treatment, other specific cleavage products may also be observed

This protocol has been validated across multiple studies and provides consistent detection of the cleaved thrombin fragment with minimal background.

How can Cleaved-F2 (R327) Antibody be incorporated into experimental designs investigating the coagulation cascade?

The Cleaved-F2 (R327) Antibody can be strategically incorporated into experimental designs investigating the coagulation cascade through several methodological approaches:

1. Temporal analysis of thrombin activation:

• Collect samples at different time points after coagulation induction

• Process for Western blotting using the Cleaved-F2 (R327) Antibody

• Quantify band intensity to determine the kinetics of thrombin cleavage

• Correlate cleavage patterns with functional coagulation assays

2. Comparative analysis across different cell types and tissues:

• Prepare lysates from various cell types (hepatocytes, endothelial cells, platelets)

• Compare baseline and stimulated levels of cleaved thrombin

• Identify cell-specific regulation of thrombin processing

• Use alongside tissue-specific markers to confirm cell identity

3. Drug intervention studies:

• Pretreat cells/samples with anticoagulants or procoagulants

• Monitor changes in thrombin cleavage patterns using the antibody

• Establish dose-response relationships

• Validate findings using functional coagulation assays

4. Genetic manipulation experiments:

• Knock down or overexpress genes involved in the coagulation cascade

• Use the antibody to assess consequent changes in thrombin processing

• Perform rescue experiments to confirm specificity

• Compare wild-type and mutant forms of coagulation factors

5. Co-immunoprecipitation studies:

• Use the antibody to pull down cleaved thrombin

• Identify interaction partners through mass spectrometry

• Confirm interactions through reciprocal co-immunoprecipitation

• Map interaction domains through deletion mutants

These methodological approaches provide a comprehensive framework for investigating thrombin activation in the context of the broader coagulation cascade.

What controls should be included when using Cleaved-F2 (R327) Antibody in immunoassays?

Proper controls are essential for ensuring the validity and reliability of results when using the Cleaved-F2 (R327) Antibody. The following controls should be included in experimental designs:

Essential Controls for Western Blotting:

• Positive Control:

  • HeLa or Jurkat cell lysates, particularly those treated with etoposide (25µM, 24 hours)

  • Known samples containing cleaved thrombin (R327)

  • Recombinant cleaved thrombin fragments (if available)

• Negative Control:

  • Cell lines with minimal thrombin expression

  • Samples treated with thrombin inhibitors

  • Lysates from cells where F2 has been knocked down by siRNA/shRNA

• Antibody Controls:

  • Primary antibody omission control (to assess secondary antibody specificity)

  • Isotype control (rabbit IgG at equivalent concentration)

  • Peptide competition assay using the immunizing peptide (derived from the internal region of human Thrombin APII)

• Loading Control:

  • Housekeeping protein detection (β-actin, GAPDH, etc.)

  • Total protein staining (Ponceau S, SYPRO Ruby)

Controls for ELISA Applications:

• Standard Curve:

  • Serial dilutions of purified cleaved thrombin

  • Synthetic peptide containing the R327 epitope

• Specificity Controls:

  • Wells coated with non-specific proteins

  • Competitive inhibition with free immunizing peptide

  • Samples depleted of thrombin via immunoprecipitation

• Technical Controls:

  • Blank wells (no primary antibody)

  • Background control (no sample)

  • Inter-assay calibrators (identical samples run on multiple plates)

Documentation and Validation:

Document all controls in your experimental records and include key controls in figures when publishing results. For validation, consider comparing results with another detection method (e.g., mass spectrometry or a different antibody targeting a separate epitope on thrombin) to confirm specificity of the observed signals.

What are the common issues encountered when using Cleaved-F2 (R327) Antibody and how can they be resolved?

Researchers may encounter several common issues when working with the Cleaved-F2 (R327) Antibody. Here are systematic approaches to identify and resolve these problems:

Issue 1: Weak or No Signal in Western Blot

Issue 2: High Background or Non-specific Bands

Issue 3: Inconsistent Results Between Experiments

Issue 4: Unexpected Molecular Weight

Implementing these systematic troubleshooting approaches will help resolve most issues encountered with the Cleaved-F2 (R327) Antibody.

How can researchers validate the specificity of Cleaved-F2 (R327) Antibody in their experimental systems?

Validating antibody specificity is crucial for generating reliable scientific data. For the Cleaved-F2 (R327) Antibody, researchers should implement the following multi-faceted validation approach:

1. Peptide Competition Assay:

• Pre-incubate the antibody with excess immunizing peptide (derived from human Thrombin APII internal region)

• Run parallel Western blots with blocked and unblocked antibody

• Specific signals should be significantly reduced or eliminated in the presence of competing peptide

• Document diminishing signal intensity with increasing peptide concentration

2. Genetic Manipulation:

• Compare samples from wild-type cells with those where F2 has been knocked down using siRNA/shRNA

• Analyze samples from F2 knockout models (if available)

• Perform rescue experiments by re-expressing F2 in knockout backgrounds

• Use CRISPR/Cas9 to introduce mutations at or near the R327 site to alter cleavage patterns

3. Multiple Detection Methods:

• Compare results with a second antibody targeting a different epitope on thrombin

• Confirm protein identity using mass spectrometry after immunoprecipitation

• Correlate antibody-based detection with activity-based assays for thrombin

• Perform immunofluorescence to verify subcellular localization patterns are consistent with known biology

4. Known Biological Responses:

• Validate detection of increased cleaved thrombin following physiological or pharmacological stimuli known to activate coagulation

• Compare levels in samples from normal versus pathological states associated with coagulation disorders

• Verify temporal patterns of cleavage following stimulation match known kinetics

• Confirm that inhibitors of thrombin activation reduce the detected signal

5. Cross-Species Reactivity Assessment:

• Test antibody performance in samples from different species

• Compare sequence homology at the epitope region across species

• Validate specific vs. non-specific signals in each new experimental system

Documentation Requirements:

• Record detailed validation procedures and results

• Maintain images of full blots with molecular weight markers

• Note antibody catalog number, lot number, and dilution used

• Document all experimental conditions during validation

This comprehensive validation strategy ensures that the observed signals truly represent cleaved thrombin rather than non-specific binding or artifacts.

How does the Cleaved-F2 (R327) Antibody compare with antibodies targeting other cleaved proteins in the coagulation cascade?

The Cleaved-F2 (R327) Antibody offers distinct advantages and limitations when compared with antibodies targeting other cleaved proteins in the coagulation cascade. Understanding these differences is crucial for experimental design and interpretation.

Comparative Analysis Table:

Key Considerations for Selection:

• Research Question Alignment:

  • Use Cleaved-F2 (R327) Antibody for studying thrombin activation specifically

  • For comprehensive coagulation pathway analysis, consider antibody panels targeting multiple factors

  • When studying apoptosis-coagulation crosstalk, pair with cleaved caspase antibodies

• Technical Compatibility:

  • The Cleaved-F2 (R327) Antibody is optimized for Western blot and ELISA applications

  • For techniques requiring native protein recognition (e.g., flow cytometry), verify antibody compatibility

  • Consider the buffer composition (PBS with 50% glycerol, 0.5% BSA, 0.02% sodium azide) when planning multiplexed assays

• Epitope Accessibility:

  • The R327 epitope may have different accessibility in various experimental conditions

  • Compare with antibodies recognizing different regions of thrombin to ensure comprehensive detection

  • For complex samples, consider using antibody combinations targeting different epitopes

This comparative analysis provides a framework for selecting the most appropriate antibody or antibody combinations based on specific research objectives within the coagulation cascade research field.

What are the methodological considerations when using Cleaved-F2 (R327) Antibody in combination with sarbecovirus neutralizing antibodies for research?

The combination of Cleaved-F2 (R327) Antibody with sarbecovirus neutralizing antibodies presents unique methodological considerations for research at the intersection of coagulation and viral pathology. Based on emerging research on broad sarbecovirus neutralizing antibodies , several important factors must be addressed:

1. Experimental Design Considerations:

• Sequential vs. Simultaneous Detection:

  • For co-detection experiments, consider potential epitope masking

  • Use sequential primary antibody incubations with thorough washing steps

  • Employ species-specific secondary antibodies with minimal cross-reactivity

  • Validate detection specificity with single-antibody controls

• Tissue/Cell Selection:

  • Focus on tissues expressing both ACE2 (sarbecovirus receptor) and coagulation factors

  • Lung endothelial cells and hepatocytes are excellent model systems

  • Consider using patient-derived samples from cases with known coagulopathy

2. Antibody Cocktail Strategies:

Given that some E1 antibodies against sarbecoviruses can function in combination with F2 or F3 counterparts , similar principles might apply when combining with Cleaved-F2 (R327) Antibody:

• Non-competing Antibody Pairs:

  • Verify that epitopes do not overlap through competition assays

  • Consider spatial arrangement of epitopes when designing detection schemes

  • Test for potential allosteric effects affecting binding

• Antibody Cocktail Ratios:

  • Optimize antibody ratios empirically (start with 1:1 and adjust)

  • Document lot-to-lot variation effects on cocktail performance

  • Verify maintenance of specificity in cocktail format

3. Technical Protocol Modifications:

For Western Blotting:

• Use dual-color detection systems with species-specific secondaries

• Consider size differences (sarbecovirus proteins vs. 19-20 kDa cleaved thrombin)

• Optimize gel percentage to resolve both target proteins adequately

For ELISA:

• Develop protocols for sequential or sandwich ELISA formats

• Test potential interference between detection systems

• Include appropriate blocking steps to prevent non-specific interactions

4. Biological Interpretation:

• Correlation Analysis:

  • Design experiments to correlate viral neutralization with coagulation markers

  • Consider temporal relationships between viral infection and coagulation activation

  • Analyze data for potential mechanistic insights into virus-induced coagulopathy

• Functional Validation:

  • Complement antibody detection with functional assays for both systems

  • Include appropriate positive and negative controls for both pathways

  • Consider three-dimensional models (e.g., organoids) for integrated pathway analysis

This methodological framework provides guidance for researchers investigating the complex interactions between viral infection and coagulation pathways, particularly relevant for understanding COVID-19-associated coagulopathy.

How can researchers integrate findings from Cleaved-F2 (R327) Antibody studies with structural analyses of broad-spectrum antibodies?

Integrating findings from Cleaved-F2 (R327) Antibody studies with structural analyses of broad-spectrum antibodies requires a multidisciplinary approach that connects coagulation biology with structural immunology. Building on insights from broad sarbecovirus neutralizing antibody research , the following methodological framework can guide this integration:

1. Structure-Function Correlation Methodology:

• Epitope Mapping Integration:

  • Compare epitope accessibility of R327 in thrombin with epitope mapping data from broad-spectrum antibodies

  • Utilize computational modeling to predict potential structural interactions

  • Apply techniques like hydrogen-deuterium exchange mass spectrometry to map conformational epitopes

  • Document epitope conservation across related proteins/variants

• Cryo-EM and X-ray Crystallography Applications:

  • Following the approach used for antibody-RBD complexes , apply similar methods to visualize Cleaved-F2 (R327) Antibody binding to thrombin

  • Generate structural models of antibody-thrombin complexes

  • Compare binding modes with those observed for broad-spectrum antibodies

  • Identify common structural features that confer broad recognition

2. Experimental Design for Integrated Analysis:

• Parallel Structural Studies:

  • Analyze structures of cleaved thrombin alone and in complex with antibody

  • Compare with structures of other relevant protein-antibody complexes

  • Identify structural elements that contribute to specificity and affinity

  • Document conformational changes upon antibody binding

• Mutational Analysis Framework:

  • Generate point mutations around the R327 site in thrombin

  • Assess effects on antibody binding and protein function

  • Correlate findings with structural predictions

  • Apply similar mutation-based approaches used in sarbecovirus antibody research

3. Data Integration Strategies:

• Computational Integration Methods:

  • Use molecular dynamics simulations to predict interaction dynamics

  • Apply machine learning algorithms to identify common structural recognition patterns

  • Develop integrated models that predict cross-reactivity

  • Create databases linking structural features with functional outcomes

• Visual Representation Standards:

  • Generate integrated structural models showing both systems

  • Create standardized visualization approaches for comparative analysis

  • Use consistent color-coding and representation schemes

  • Develop interactive models for exploration of binding interfaces

4. Translational Research Applications:

• Therapeutic Development Framework:

  • Apply principles from cocktail antibody design to thrombin-targeting strategies

  • Identify non-competing antibody pairs that could act synergistically

  • Design bispecific antibodies based on structural insights

  • Validate predictions through functional assays

• Diagnostic Development Pathway:

  • Leverage structural insights to improve detection specificity

  • Design simplified assays based on critical epitope regions

  • Develop multiplexed detection systems that integrate both marker types

  • Validate diagnostic accuracy across diverse sample types

This integrated methodological framework provides researchers with a systematic approach to connect structural insights from different antibody systems, potentially revealing common principles of antibody recognition and function that could advance both fields simultaneously.